Treatment with CHX increased the expression of mutant PTC-mRNAs derived from MSI target genes (e.g., TGFBR2, MSH3, or HSP110) in MSI vs MSS CRC cell lines (Fig. 2b). The gene discussed is HSPH1; the disease is colorectal carcinoma.